Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
ADAMTS-13, the metalloprotease that disposes physiologically of the most thrombogenic multimers of von Willebrand factor (VWF), tends to be low in plasma when VWF is high. We evaluated the behaviour of these two proteins in naturally occurring, experimental and clinical situations associated with VWF levels spanning from undetectable to supranormal. ADAMTS-13 was approximately 10% higher (and VWF 35% lower) in 65 healthy individuals of blood group O than in 65 individuals of groups A, B and AB. Thirty-three patients with type 3 von Willebrand disease (VWD) with undetectable plasma VWF had approximately 35% higher levels of ADAMTS-13 than a comparable group of healthy individuals with normal VWF. When VWF was raised to supranormal levels by desmopressin (DDAVP) in 10 healthy volunteers, ADAMTS-13 decreased by approximately 20%, with no change of the protease in three patients with severe VWD who had no post-DDAVP VWF rise. When VWF was raised from very low to normal levels by the infusion of VWF-containing plasma concentrates in four patients with type 3 VWD and one with type 1 VWD plasma, ADAMTS-13 decreased in parallel. These data show that throughout a large spectrum of plasma VWF levels there is a negative association between this protein and the activity of its major cleaving protease.
Mannucci
Pier Mannuccio
PM
Department of Internal Medicine, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, University of Milan, Milan, Italy. pmmannucci@libero.it
Capoferri
Cristina
C
Canciani
Maria Teresa
MT
D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; D000328:Adult; D001789:Blood Group Antigens; D016022:Case-Control Studies; D003894:Deamino Arginine Vasopressin; D005169:Factor VIII / Q000627:therapeutic use; D005260:Female; D006490:Hemostatics; D006801:Humans; D008297:Male; D008666:Metalloendopeptidases / Q000097:blood*; D008875:Middle Aged; D018709:Statistics, Nonparametric; D014842:von Willebrand Diseases / Q000097:blood* / Q000188:drug therapy; D014841:von Willebrand Factor / Q000032:analysis* / Q000627:therapeutic use
D001789:Blood Group Antigens; D006490:Hemostatics; D014841:von Willebrand Factor; D005169:Factor VIII; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human; D003894:Deamino Arginine Vasopressin